James E. Thompson

Hematologic Oncology
Buffalo Spree Top Doctor 2024

Dr. Thompson is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2024

Cancers Treated:

Specializing In:

Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Chronic myeloid leukemia (CML) Hematologic Oncology Myelodysplastic syndrome (MDS) Myeloproliferative diseases (MPD)

Research Interests:

Management of CML with a focus on treatment free remission (TFR) and novel treatments Clinical informatics and optimization of the Electronic Health Record (EHR) to enhance patient care

About James E. Thompson


Roswell Park Comprehensive Cancer Center
  • Associate Professor
  • Department of Medicine
  • Associate Chief Medical Information Officer - Medicine


Education and Training:

  • MD - Columbia University College of Physicians & Surgeons, New York, NY
  • MS - Medical Informatics, Northwestern University, Evanston, IL


  • University of Pennsylvania, Philadelphia, PA


  • University of Pennsylvania, Philadelphia, PA

Board Certification:

  • Hematology, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Clinical Informatics, American Board of Preventative Medicine

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed

1. Hanif, A, Wang, ES, Thompson, JE, Baron, JI, Walsh, MD, & Griffiths, EA (2018). Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia. Leuk Lymphoma 59(8)2011-2013.
2. Vachhani P, Al Yacoub R, Miller A, Zhang F, Cronin TL, Ontiveros EP, Thompson JE, Griffiths EA, Wang ES. (2019) Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience. Leuk Res 75:29-35.
3. Flynn KE, Mauro MJ, Gemlyn G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E. (2019) Patients’ perspectives on the definition of cure in chronic myeloid leukemia. Leuk Res. 80:40-42.
4. Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E. (2019) Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Oncologist 24(9):1253-1258.
5. Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E. (2020) In Reply. Oncologist 25(4):e744-e745
6. Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. (2021) Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol 7(1):42-50
7. Przespolewski A, Muppidi MR, Freyer CW, Ji W, Cronin TL, Thota S, Griffiths EA, Thompson JE, Ontiveros EP, Baron J, Elshoury A, Wang ES. (2021) Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. Leuk Lymphoma. Feb 16;:1-6. [Epub ahead of print]